ELF3

Summary

Gene Symbol: ELF3
Description: E74 like ETS transcription factor 3
Alias: EPR-1, ERT, ESE-1, ESX, ETS-related transcription factor Elf-3, E74-like factor 3 (ETS domain transcription factor, serine box, epithelial-specific), E74-like factor 3 (ets domain transcription factor), E74-like factor 3 (ets domain transcription factor, epithelial-specific ), epithelial-restricted with serine box, epithelium-restricted Ets protein ESX, epithelium-specific Ets transcription factor 1, ets domain transcription factor, serine box (epithelial-specific)
Species: human
Products:     ELF3

Top Publications

  1. Andreoli J, Jang S, Chung E, Coticchia C, Steinert P, Markova N. The expression of a novel, epithelium-specific ets transcription factor is restricted to the most differentiated layers in the epidermis. Nucleic Acids Res. 1997;25:4287-95 pubmed
    ..We show that two epidermal marker genes whose expression coincides with that of jen are transregulated by this protein in a complex mode which involves interactions with other transcriptional regulators such as Sp1 and AP1. ..
  2. Prescott J, Koto K, Singh M, Gutierrez Hartmann A. The ETS transcription factor ESE-1 transforms MCF-12A human mammary epithelial cells via a novel cytoplasmic mechanism. Mol Cell Biol. 2004;24:5548-64 pubmed
    ..These studies not only describe a unique ETS factor transformation mechanism but also establish a new paradigm for cell transformation in general. ..
  3. Otero M, Plumb D, Tsuchimochi K, Dragomir C, Hashimoto K, Peng H, et al. E74-like factor 3 (ELF3) impacts on matrix metalloproteinase 13 (MMP13) transcriptional control in articular chondrocytes under proinflammatory stress. J Biol Chem. 2012;287:3559-72 pubmed publisher
    ..Here we report that ELF3 directly controls MMP13 promoter activity by targeting an E26 transformation-specific sequence binding site at ..
  4. Chang C, Scott G, Kuo W, Xiong X, Suzdaltseva Y, Park J, et al. ESX: a structurally unique Ets overexpressed early during human breast tumorigenesis. Oncogene. 1997;14:1617-22 pubmed
    ..Recombinant protein encoded by ESX (for epithelial-restricted with serine box) exhibits Ets-like DNA binding specificity in electrophoretic mobility ..
  5. Tymms M, Ng A, Thomas R, Schutte B, Zhou J, Eyre H, et al. A novel epithelial-expressed ETS gene, ELF3: human and murine cDNA sequences, murine genomic organization, human mapping to 1q32.2 and expression in tissues and cancer. Oncogene. 1997;15:2449-62 pubmed
    ..We identify a novel ETS family member, ELF3, and report its human and murine cDNA sequences...
  6. Choi S, Yi Y, Kim Y, Kato M, Chang J, Chung H, et al. A novel ets-related transcription factor, ERT/ESX/ESE-1, regulates expression of the transforming growth factor-beta type II receptor. J Biol Chem. 1998;273:110-7 pubmed
    ..The novel ets-related transcription factor (ERT) showed a homology with the ETS DNA-binding domain...
  7. Schedin P, Eckel Mahan K, McDaniel S, Prescott J, Brodsky K, Tentler J, et al. ESX induces transformation and functional epithelial to mesenchymal transition in MCF-12A mammary epithelial cells. Oncogene. 2004;23:1766-79 pubmed
    b>ESX is an epithelial-restricted member of a large family of transcription factors known as the Ets family...
  8. Kaplan M, Wang X, Xu H, Dosik M. Partially unspliced and fully spliced ELF3 mRNA, including a new Alu element in human breast cancer. Breast Cancer Res Treat. 2004;83:171-87 pubmed
    ..GC3 proved to be a fragment of intron 7 of the ELF3 gene, an ets family transcription factor, amplified in the breast cancer cell line...
  9. Manavathi B, Rayala S, Kumar R. Phosphorylation-dependent regulation of stability and transforming potential of ETS transcriptional factor ESE-1 by p21-activated kinase 1. J Biol Chem. 2007;282:19820-30 pubmed
    ..These findings provide novel insights into the mechanism of transformation potential of ESE-1 and discovered that ESE-1 functions are coordinately regulated by Pak1 phosphorylation and beta-TrCP-dependent ubiquitin-proteasome pathways. ..

More Information

Publications123 found, 100 shown here

  1. Nakarai C, Osawa K, Matsubara N, Ikeuchi H, Yamano T, Okamura S, et al. Significance of ELF3 mRNA expression for detection of lymph node metastases of colorectal cancer. Anticancer Res. 2012;32:3753-8 pubmed
    ..The purpose of our study was to investigate the effectiveness of E74-like factor 3 (ELF3) and carcinoembryonic antigen (CEA) as useful markers to detect LN metastases in CRC...
  2. Oettgen P, Alani R, Barcinski M, Brown L, Akbarali Y, Boltax J, et al. Isolation and characterization of a novel epithelium-specific transcription factor, ESE-1, a member of the ets family. Mol Cell Biol. 1997;17:4419-33 pubmed
    ..Due to the important role that other ets factors play in cellular differentiation, ESE-1 is expected to be a critical regulator of epithelial cell differentiation. ..
  3. Chang C, Scott G, Baldwin M, Benz C. Exon 4-encoded acidic domain in the epithelium-restricted Ets factor, ESX, confers potent transactivating capacity and binds to TATA-binding protein (TBP). Oncogene. 1999;18:3682-95 pubmed
    ..To understand the biological properties associated with a recently described epithelium-restricted Ets factor ESX, an 11 kb fragment from the 1q32.2 genomically localized human gene was cloned and analysed...
  4. Shatnawi A, Norris J, Chaveroux C, Jasper J, Sherk A, McDonnell D, et al. ELF3 is a repressor of androgen receptor action in prostate cancer cells. Oncogene. 2014;33:862-71 pubmed publisher
    ..Here we report that E74-like factor 3 (ELF3), a member of the ETS family of transcription factors, is a repressor of AR transcriptional activity...
  5. Longoni N, Sarti M, Albino D, Civenni G, Malek A, Ortelli E, et al. ETS transcription factor ESE1/ELF3 orchestrates a positive feedback loop that constitutively activates NF-?B and drives prostate cancer progression. Cancer Res. 2013;73:4533-47 pubmed publisher
    ..Here, we report a novel mechanism leading to oncogenic activation of the ETS factor ESE1/ELF3 in prostate tumors. ESE1/ELF3 was overexpressed in human primary and metastatic tumors...
  6. Lin S, Chien Y, Chiang W, Liu Y, Lien C, Chen C. Genetic mapping of ASIC4 and contrasting phenotype to ASIC1a in modulating innate fear and anxiety. Eur J Neurosci. 2015;41:1553-68 pubmed publisher
    ..To trace the expression of this ion channel, we generated the ASIC4-knockout/CreERT(2)-knockin (Asic4(Cre) (ERT) (2)) mouse line...
  7. Parmar K, Itankar P, Joshi A, Prasad S. Anti-psoriatic potential of Solanum xanthocarpum stem in Imiquimod-induced psoriatic mice model. J Ethnopharmacol. 2017;198:158-166 pubmed publisher
    ..Ethanolic stems extract of Solanum xanthocarpum (ESX) was first subjected to phytochemical screening and quantification of identified phytoconstituents, which was ..
  8. Tomioka H. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship. Curr Pharm Des. 2014;20:4305-6 pubmed
    ..Serafini, Alessandro Cascioferro, Roland Brosch, and Riccardo Manganelli review the current knowledge on MTB T7SS/ESX secretion systems and their impact on MTB physiology and virulence, and the possible approaches to develop T7SS/ESX ..
  9. Huang D, Bao L. Mycobacterium tuberculosis EspB protein suppresses interferon-γ-induced autophagy in murine macrophages. J Microbiol Immunol Infect. 2016;49:859-865 pubmed publisher
    ..Although the early secretory antigenic target 6 (ESAT-6) system 1 (ESX-1) secretion-associated protein B (EspB) of Mtb is strongly linked to immunogenicity and virulence of this organism,..
  10. Maan S, Maan N, Batra K, Kumar A, Gupta A, Rao P, et al. Reverse transcription loop-mediated isothermal amplification assays for rapid identification of eastern and western strains of bluetongue virus in India. J Virol Methods. 2016;234:65-74 pubmed publisher
    ..The accelerated eRT-LAMP and wRT-LAMP assays generated detectable levels of amplified DNA, down to 0...
  11. Jiao Y, Wang Y, Yuan L. [Allelopathic effects of extracts from tuberous roots of Aconitum carmichaeli on three pasture grasses]. Zhongguo Zhong Yao Za Zhi. 2015;40:4155-9 pubmed
    ..Seed germination of M. sativa was stimulated by low ERT concentration (0.01 x g(-1)), while all of pasture grass seeds germinated poorly in solution with 1.00 g x L(-1)...
  12. Sellin J, Schulze H, Paradis M, Gosejacob D, Papan C, Shevchenko A, et al. Characterization of Drosophila Saposin-related mutants as a model for lysosomal sphingolipid storage diseases. Dis Model Mech. 2017;10:737-750 pubmed publisher
    ..While some LSDs can be efficiently treated by enzyme replacement therapy (ERT), this is not possible if the nervous system is affected due to the presence of the blood-brain barrier...
  13. Lauritsen C, Chua A, Nahas S. Current Treatment Options: Headache Related to Menopause-Diagnosis and Management. Curr Treat Options Neurol. 2018;20:7 pubmed publisher
    ..Estrogen replacement therapy (ERT) in patients with migraine with aura (MA) may increase the risk of ischemic stroke; however, the effect is likely ..
  14. Sestito S, Ceravolo F, Concolino D. Anderson-Fabry disease in children. Curr Pharm Des. 2013;19:6037-45 pubmed
    ..Clinical trials of enzyme replacement therapy (ERT) with agalsidase alfa and agalsidase beta have been conducted in children, with clinical and pharmacodinamc effects ..
  15. Lavalle L, Thomas A, Beaton B, Ebrahim H, Reed M, Ramaswami U, et al. Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S mutation. PLoS ONE. 2018;13:e0193550 pubmed publisher
    ..Plasma globotriaosylsphingosine (lyso-Gb3) was analysed prior to ERT in 84 patients. N215S patients showed later symptom onset (males: p< 0.0001, females: p<0...
  16. Donida B, Marchetti D, Biancini G, Deon M, Manini P, da Rosa H, et al. Oxidative stress and inflammation in mucopolysaccharidosis type IVA patients treated with enzyme replacement therapy. Biochim Biophys Acta. 2015;1852:1012-9 pubmed publisher
    ..We analyzed urine and blood samples from patients under ERT (n=17) and healthy age-matched controls (n=10-15)...
  17. Gómez A, Delconte M, Altamirano G, Vigezzi L, Bosquiazzo V, Barbisan L, et al. Perinatal Exposure to Bisphenol A or Diethylstilbestrol Increases the Susceptibility to Develop Mammary Gland Lesions After Estrogen Replacement Therapy in Middle-Aged Rats. Horm Cancer. 2017;8:78-89 pubmed publisher
    ..Here, we assessed the effects induced by estrogen replacement therapy (ERT) in ovariectomized (OVX) middle-aged rats and whether perinatal exposure to diethylstilbestrol (DES) or bisphenol A ..
  18. Iijima O, Miyake K, Watanabe A, Miyake N, Igarashi T, Kanokoda C, et al. Prevention of Lethal Murine Hypophosphatasia by Neonatal Ex Vivo Gene Therapy Using Lentivirally Transduced Bone Marrow Cells. Hum Gene Ther. 2015;26:801-12 pubmed publisher
    ..In 2015, enzyme replacement therapy (ERT) using recombinant bone-targeted TNALP with deca-aspartate (D10) motif was approved to treat pediatric HPP patients ..
  19. Madsen C, Christensen E, Nielsen R, Mogensen H, Rasmussen A, Feldt Rasmussen U. Enzyme Replacement Therapy During Pregnancy in Fabry Patients : Review of Published Cases of Live Births and a New Case of a Severely Affected Female with Fabry Disease and Pre-eclampsia Complicating Pregnancy. JIMD Rep. 2018;: pubmed publisher
    ..Impact of FD and treatment with enzyme replacement (ERT) on foetal development is undisclosed.A 38-year-old primigravida with FD (G85N) is reported...
  20. Tomatsu S, Alméciga Díaz C, Montaño A, Yabe H, Tanaka A, Dung V, et al. Therapies for the bone in mucopolysaccharidoses. Mol Genet Metab. 2015;114:94-109 pubmed publisher
    ..Enzyme replacement therapy (ERT), hematopoietic stem cell transplantation (HSCT), and gene therapy are available or in development for some types ..
  21. Lu J, Nelvagal H, Wang L, Birnbaum S, Cooper J, Hofmann S. Intrathecal enzyme replacement therapy improves motor function and survival in a preclinical mouse model of infantile neuronal ceroid lipofuscinosis. Mol Genet Metab. 2015;116:98-105 pubmed publisher
    ..studies involving other lysosomal storage disorders, such as CLN2/TPP1 deficiency, for which intraventricular ERT is being offered in clinical trials...
  22. Chuang C, Lin H, Wang T, Huang Y, Chan M, Liao H, et al. Status of newborn screening and follow up investigations for Mucopolysaccharidoses I and II in Taiwan. Orphanet J Rare Dis. 2018;13:84 pubmed publisher
    ..The early initiation of enzyme replacement therapy (ERT) can slow or prevent the development of severe clinical manifestations...
  23. Nascimbeni F, Dalla Salda A, Carubbi F. Energy balance, glucose and lipid metabolism, cardiovascular risk and liver disease burden in adult patients with type 1 Gaucher disease. Blood Cells Mol Dis. 2018;68:74-80 pubmed publisher
    ..and hypolipidemia with markedly reduced HDL-cholesterol levels, partially reverted by enzyme replacement therapy (ERT) or substrate reduction therapy (SRT)...
  24. Chen K, Chien Y, Wang K, Leu H, Hsiao C, Lai Y, et al. Evaluation of Proinflammatory Prognostic Biomarkers for Fabry Cardiomyopathy With Enzyme Replacement Therapy. Can J Cardiol. 2016;32:1221.e1-1221.e9 pubmed publisher
    ..Enzyme replacement therapy (ERT) can reduce the severity of Fabry cardiomyopathy (FC), but whether ERT could attenuate proinflammatory cytokines in ..
  25. Kuperus E, Kruijshaar M, Wens S, de Vries J, Favejee M, van der Meijden J, et al. Long-term benefit of enzyme replacement therapy in Pompe disease: A 5-year prospective study. Neurology. 2017;: pubmed publisher
    To determine the effect of enzyme replacement therapy (ERT) after 5 years and to identify predictors for a favorable response because few data are available on the long-term efficacy of ERT in Pompe disease.
  26. Karimian Z, Whitley C, Rudser K, Utz J. Delayed Infusion Reactions to Enzyme Replacement Therapies. JIMD Rep. 2017;34:63-70 pubmed publisher
    There are currently ten intravenous enzyme replacement therapy (ERT) products available for the treatment of eight different lysosomal diseases (LD) in the USA. Additional ERT products are in clinical trials...
  27. McMurtrey C, Harriff M, Swarbrick G, Duncan A, Cansler M, Null M, et al. T cell recognition of Mycobacterium tuberculosis peptides presented by HLA-E derived from infected human cells. PLoS ONE. 2017;12:e0188288 pubmed publisher
    ..Here we identified 28 Mtb ligands derived from 13 different source proteins, including the Esx family of proteins...
  28. Hirschburger D, Müller M, Voegele R, Link T. Reference Genes in the Pathosystem Phakopsora pachyrhizi/ Soybean Suitable for Normalization in Transcript Profiling. Int J Mol Sci. 2015;16:23057-75 pubmed publisher
    ..For studies omitting the resting spore and the appressorium stages a combination of Elf3 and RPS9, or PKD and GAPDH should be used...
  29. Lin H, Chuang C, Chen M, Lin S, Hung C, Chang C, et al. Cardiac structure and function and effects of enzyme replacement therapy in patients with mucopolysaccharidoses I, II, IVA and VI. Mol Genet Metab. 2016;117:431-7 pubmed publisher
    While enzyme replacement therapy (ERT) has been shown to improve endurance and joint mobility for patients with mucopolysaccharidoses (MPS) I, II, IVA and VI, the impact of ERT on cardiac abnormalities remains uncertain...
  30. Otero M, Peng H, Hachem K, Culley K, Wondimu E, Quinn J, et al. ELF3 modulates type II collagen gene (COL2A1) transcription in chondrocytes by inhibiting SOX9-CBP/p300-driven histone acetyltransferase activity. Connect Tissue Res. 2017;58:15-26 pubmed publisher
    We showed previously that E74-like factor 3 (ELF3) protein levels are increased in osteoarthritic (OA) cartilage, that ELF3 accounts for inflammatory cytokine-driven MMP13 gene expression, and that, upon induction by interleukin-1?, ELF3 ..
  31. Crowe L, Yaplito Lee J, Anderson V, Peters H. Cognitive and behaviour profiles of children with mucopolysaccharidosis Type II. Cogn Neuropsychol. 2017;34:347-356 pubmed publisher
    ..Enzyme replacement therapy (ERT) can stabilize physical symptoms and has become standard treatment...
  32. Tylki Szymańska A, Szymańska Rożek P, Hasiński P, Ługowska A. Plasma chitotriosidase activity versus plasma glucosylsphingosine in wide spectrum of Gaucher disease phenotypes - A statistical insight. Mol Genet Metab. 2018;123:495-500 pubmed publisher
    ..We found that the treatment of GD with enzyme replacement therapy (ERT) changes the distribution of the disease biomarkers; their levels follow a normal distribution only in untreated ..
  33. Solanki G, Sun P, Martin K, Hendriksz C, Lampe C, Guffon N, et al. Cervical cord compression in mucopolysaccharidosis VI (MPS VI): Findings from the MPS VI Clinical Surveillance Program (CSP). Mol Genet Metab. 2016;118:310-8 pubmed publisher
    ..There was an insufficient number of subjects with both pre- and post-enzyme replacement therapy (ERT) MRI data to determine any association between ERT and cervical cord compression...
  34. Sato Y, Ida H, Ohashi T. Anti-BlyS antibody reduces the immune reaction against enzyme and enhances the efficacy of enzyme replacement therapy in Fabry disease model mice. Clin Immunol. 2017;178:56-63 pubmed publisher
    Formation of antibodies against a therapeutic enzyme is an important complication during enzyme replacement therapy (ERT) for lysosomal storage diseases...
  35. Dosanjh A, Paurazas S, Askar M. The Effect of Temperature on Cyclic Fatigue of Nickel-titanium Rotary Endodontic Instruments. J Endod. 2017;43:823-826 pubmed publisher
    ..EdgeFile; EdgeEndo, Albuquerque, NM], VB group [Vortex Blue; Dentsply Tulsa Dental Specialties, Tulsa, OK], and ESX group [ESX; Brasseler USA, Savannah, GA]) of size 25 with a ...
  36. Papadopoulos C, Orlikowski D, Prigent H, Lacour A, Tard C, Furby A, et al. Effect of enzyme replacement therapy with alglucosidase alfa (Myozyme®) in 12 patients with advanced late-onset Pompe disease. Mol Genet Metab. 2017;122:80-85 pubmed publisher
    The efficacy of enzyme replacement therapy (ERT) in patients at an advanced stage of Pompe disease has only been addressed in a few studies...
  37. Santos D, Tiscornia G. Induced Pluripotent Stem Cell Modeling of Gaucher's Disease: What Have We Learned?. Int J Mol Sci. 2017;18: pubmed publisher
    ..Current treatment options are enzyme replacement therapy (ERT) and substrate reduction therapy (SRT)...
  38. Wilcox W, Feldt Rasmussen U, Martins A, Ortiz A, Lemay R, Jovanovic A, et al. Improvement of Fabry Disease-Related Gastrointestinal Symptoms in a Significant Proportion of Female Patients Treated with Agalsidase Beta: Data from the Fabry Registry. JIMD Rep. 2018;38:45-51 pubmed publisher
    ..To further understand the effects of sustained enzyme replacement therapy (ERT) with agalsidase beta on gastrointestinal symptoms in heterozygotes, a data analysis of female patients enrolled in ..
  39. Rodrigues J, Azevedo O, Sousa N, Cunha D, Mexedo A, Fonseca R. Inner ear involvement in Fabry disease: Clinical and audiometric evaluation of a large cohort of patients followed in a reference centre. Eur J Med Genet. 2018;61:341-347 pubmed publisher
    ..A stabilization of hearing function has been reported with enzyme replacement therapy (ERT)...
  40. Murugesan V, Chuang W, Liu J, Lischuk A, Kacena K, Lin H, et al. Glucosylsphingosine is a key biomarker of Gaucher disease. Am J Hematol. 2016;91:1082-1089 pubmed publisher
    ..Propensity scores were used to match patients on treatment mode: Enzyme Replacement Therapy (ERT) vs. Eliglustat Tartrate SRT (ELI-SRT). Plasma Lyso-GL1 levels in healthy controls averaged 1.5 ng/ml (1.3-1...
  41. Parini R, Deodato F, Di Rocco M, Lanino E, Locatelli F, Messina C, et al. Open issues in Mucopolysaccharidosis type I-Hurler. Orphanet J Rare Dis. 2017;12:112 pubmed publisher
    ..Enzyme replacement therapy (ERT) with human recombinant laronidase has also been demonstrated to be effective in ameliorating the clinical ..
  42. Fukuhara Y, Fuji N, Yamazaki N, Hirakiyama A, Kamioka T, Seo J, et al. A molecular analysis of the GAA gene and clinical spectrum in 38 patients with Pompe disease in Japan. Mol Genet Metab Rep. 2018;14:3-9 pubmed publisher
    ..clinical courses may be influenced by the timing of the diagnosis and treatment; for example, in 2007, an ERT orphan drug for treatment of Pompe disease, Alglucosidase alfa, was made available in Japan, and there were 5 (5/6 ..
  43. Tsuboi K, Yamamoto H. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients. BMC Pharmacol Toxicol. 2017;18:43 pubmed publisher
    ..Enzyme-replacement-therapy (ERT) products for FD currently used include agalsidase alfa and agalsidase beta...
  44. Asari M, Okuda K, Hoshina C, Omura T, Tasaki Y, Shiono H, et al. Multicolor-based discrimination of 21 short tandem repeats and amelogenin using four fluorescent universal primers. Anal Biochem. 2016;494:16-22 pubmed publisher
    ..The selected 22 loci were also analyzed using two commercial kits (the AmpFLSTR Identifiler Kit and the PowerPlex ESX 17 System), and results for two loci (D19S433 and D16S539) were discordant between these kits due to mutations at ..
  45. Saiz M, Rios Rivas R, Alvarez J, Lorente J, Villegas Carmona D, Ramirez Flores E, et al. Genetic variation of 17 STR loci in a Mexican Mestizo population from Mexico City. Int J Legal Med. 2016;130:1505-1507 pubmed
    Genetic data from 17 autosomal short tandem repeat (STR) loci found in the Powerplex® ESX 17 System (Promega, Madison, WI, USA) was evaluated in 162 unrelated Mexican Mestizo individuals from Mexico City...
  46. Phan T, Ummels R, Bitter W, Houben E. Identification of a substrate domain that determines system specificity in mycobacterial type VII secretion systems. Sci Rep. 2017;7:42704 pubmed publisher
    ..There are up to five mycobacterial T7S systems, named ESX-1 to ESX-5, at least three of which specifically secrete a different subset of substrates...
  47. Scott O, Kim V, Reid B, Pham Huy A, Atkinson A, Aiuti A, et al. Long-Term Outcome of Adenosine Deaminase-Deficient Patients-a Single-Center Experience. J Clin Immunol. 2017;37:582-591 pubmed publisher
    ..Management options for ADA-deficient patients include enzyme replacement therapy (ERT), hematopoietic stem cell transplantation (HSCT), and gene therapy (GT)...
  48. Broomfield A, Fletcher J, Davison J, Finnegan N, Fenton M, Chikermane A, et al. Response of 33 UK patients with infantile-onset Pompe disease to enzyme replacement therapy. J Inherit Metab Dis. 2016;39:261-71 pubmed publisher
    Enzyme replacement therapy (ERT) for infantile-onset Pompe disease has been commercially available for almost 10 years. We report the experience of its use in a cohort treated at three specialist lysosomal treatment centres in the UK...
  49. Gröschel M, Sayes F, Shin S, Frigui W, Pawlik A, Orgeur M, et al. Recombinant BCG Expressing ESX-1 of Mycobacterium marinum Combines Low Virulence with Cytosolic Immune Signaling and Improved TB Protection. Cell Rep. 2017;18:2752-2765 pubmed publisher
    ..A feature of BCG is the partial deletion of the ESX-1 type VII secretion system, which governs phagosomal rupture and cytosolic pattern recognition, key intracellular ..
  50. Chen K, Chou Y, Hsiao C, Chien Y, Wang K, Lai Y, et al. Amelioration of serum 8-OHdG level by enzyme replacement therapy in patients with Fabry cardiomyopathy. Biochem Biophys Res Commun. 2017;486:293-299 pubmed publisher
    ..The objective of this study was to evaluate the effect of enzyme replacement therapy (ERT) on the level of 8-OHdG in patients with Fabry cardiomyopathy and the clinical evolution of Fabry cardiomyopathy...
  51. Schupf N, Lee J, Pang D, Zigman W, Tycko B, KRINSKY MCHALE S, et al. Epidemiology of estrogen and dementia in women with Down syndrome. Free Radic Biol Med. 2018;114:62-68 pubmed publisher
    ..To date, no clinical trials of estrogen or hormone replacement therapy (ERT/HRT) have been published for women with Down syndrome...
  52. Muenzer J, Giugliani R, Scarpa M, Tylki Szymanska A, Jego V, Beck M. Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS). Orphanet J Rare Dis. 2017;12:161 pubmed publisher
    ..Treatment is available in the form of enzyme replacement therapy (ERT) with recombinant I2S...
  53. Alvarez E, Northwood I, Gonzalez F, Latour D, Seth A, Abate C, et al. Pro-Leu-Ser/Thr-Pro is a consensus primary sequence for substrate protein phosphorylation. Characterization of the phosphorylation of c-myc and c-jun proteins by an epidermal growth factor receptor threonine 669 protein kinase. J Biol Chem. 1991;266:15277-85 pubmed
    A growth factor-stimulated (MAP2-related) protein kinase, ERT, that phosphorylates the epidermal growth factor receptor at Thr669 has been purified from KB human tumor cells by Northwood and co-workers (Northwood, I. C., Gonzalez, F. A...
  54. Yasuda E, Suzuki Y, Shimada T, Sawamoto K, MacKenzie W, Theroux M, et al. Activity of daily living for Morquio A syndrome. Mol Genet Metab. 2016;118:111-22 pubmed publisher
    ..treated with hematopoietic stem cell transplantation (HSCT), 33 patients treated with enzyme replacement therapy (ERT) for more than a year, and 45 untreated patients...
  55. Bosserman R, Nguyen T, Sanchez K, Chirakos A, Ferrell M, Thompson C, et al. WhiB6 regulation of ESX-1 gene expression is controlled by a negative feedback loop in Mycobacterium marinum. Proc Natl Acad Sci U S A. 2017;114:E10772-E10781 pubmed publisher
    b>ESX (ESAT-6 system) export systems play diverse roles across mycobacterial species. Interestingly, genetic disruption of ESX systems in different species does not result in an accumulation of protein substrates in the mycobacterial cell...
  56. Loscher W, Huemer M, Stulnig T, Simschitz P, Iglseder S, Eggers C, et al. Pompe disease in Austria: clinical, genetic and epidemiological aspects. J Neurol. 2018;265:159-164 pubmed publisher
    ..The number of patients receiving enzyme replacement therapy (ERT) was obtained from the pharmaceutical company providing alglucosidase alfa...
  57. Lehrke H, Heimbach J, Wu T, Jenkins S, Gores G, Rosen C, et al. Prognostic Significance of the Histologic Response of Perihilar Cholangiocarcinoma to Preoperative Neoadjuvant Chemoradiation in Liver Explants. Am J Surg Pathol. 2016;40:510-8 pubmed publisher
    ..We aimed to assess the value of extent of residual tumor (ERT) and other pathologic factors following chemoradiation in predicting outcome; 152 liver explants with pCCA treated ..
  58. Martín Banderas L, Holgado M, Durán Lobato M, Infante J, Alvarez Fuentes J, Fernandez Arevalo M. Role of Nanotechnology for Enzyme Replacement Therapy in Lysosomal Diseases. A Focus on Gaucher's Disease. Curr Med Chem. 2016;23:929-52 pubmed
    ..Up to date, the most promising therapy for most LSDs is enzyme-replacement therapy (ERT), which provides patients with the corresponding active enzyme...
  59. Lee C, Gupta S, Wang J, Johnson E, Crofford L, Marshall J, et al. Epithelium-specific Ets transcription factor-1 acts as a negative regulator of cyclooxygenase-2 in human rheumatoid arthritis synovial fibroblasts. Cell Biosci. 2016;6:43 pubmed publisher
    ..ESE-1 acts as a negative regulator of COX-2 in human RASFs and its effect on COX-2 is NF?B-independent. ..
  60. Hargreaves A, Mothersill O, Anderson M, Lawless S, Corvin A, Donohoe G. Detecting facial emotion recognition deficits in schizophrenia using dynamic stimuli of varying intensities. Neurosci Lett. 2016;633:47-54 pubmed publisher
    ..To this end an emotion recognition task (ERT) designed by Montagne (2007) was adapted and employed...
  61. Weng Z, Gao Q, Wang F, Zhao G, Yin F, Cai B, et al. Positive skeletal effect of two ingredients of Psoralea corylifolia L. on estrogen deficiency-induced osteoporosis and the possible mechanisms of action. Mol Cell Endocrinol. 2015;417:103-13 pubmed publisher
    Estrogen replacement therapy (ERT) is utilized as a major regime for treatment of postmenopausal osteoporosis at present...
  62. Taipale M, Jakkula E, Kämäräinen O, Gao P, Skarp S, Barral S, et al. Targeted re-sequencing of linkage region on 2q21 identifies a novel functional variant for hip and knee osteoarthritis. Osteoarthritis Cartilage. 2016;24:655-63 pubmed publisher
    ..42 under dominant model of inheritance. Insertion creates a recognition sequence for ELF3 and HMGA1 transcription factors...
  63. Mac Lochlainn D, McKechnie D, Mehta A, Hughes D. The utility of the FIPI score in predicting long-term clinical outcomes in patients with Fabry disease receiving enzyme replacement therapy with agalsidase alfa. Mol Genet Metab. 2018;123:154-158 pubmed publisher
    ..Enzyme replacement therapy (ERT) is commercially available and has been demonstrated to improve cardiac and renal outcomes...
  64. Wilks M, Blaauboer B, Schulte Hermann R, Wallace H, Galli C, Haag Grönlund M, et al. The European Registered Toxicologist (ERT): Current status and prospects for advancement. Toxicol Lett. 2016;259:151-5 pubmed publisher
    Following its inception in 1994, the certification of European Registered Toxicologists (ERT) by EUROTOX has been recognized as ensuring professional competence as well as scientific integrity and credibility...
  65. Press M, Queitsch C. Variability in a Short Tandem Repeat Mediates Complex Epistatic Interactions in Arabidopsis thaliana. Genetics. 2017;205:455-464 pubmed publisher
    ..We previously reported that natural ELF3 polyglutamine variants cause reciprocal genetic incompatibilities in two divergent Arabidopsis thaliana backgrounds...
  66. Shimogawa H, Kwon Y, Mao Q, Kawazoe Y, Choi Y, Asada S, et al. A wrench-shaped synthetic molecule that modulates a transcription factor-coactivator interaction. J Am Chem Soc. 2004;126:3461-71 pubmed
    ..molecule that impairs the transcription of the Her2 oncogene by disrupting association of transcription factor ESX with its coactivator Sur-2...
  67. Horovitz D, Acosta A, Giugliani R, Hlavata A, Hlavatá K, Tchan M, et al. Alternative laronidase dose regimen for patients with mucopolysaccharidosis I: a multinational, retrospective, chart review case series. Orphanet J Rare Dis. 2016;11:51 pubmed publisher
    Enzyme replacement therapy (ERT) with laronidase (recombinant human ?-L-iduronidase, Aldurazyme®) is indicated for non-neurological signs and symptoms of mucopolysaccharidosis type I (MPS I)...
  68. van der Ploeg A, Carlier P, Carlier R, Kissel J, Schoser B, Wenninger S, et al. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study. Mol Genet Metab. 2016;119:115-23 pubmed publisher
    ..In this population, enzyme replacement therapy (ERT) with alglucosidase alfa has been shown to stabilize respiratory function and improve mobility and muscle strength...
  69. Mortimer T, Weber A, PEPPERELL C. Evolutionary Thrift: Mycobacteria Repurpose Plasmid Diversity during Adaptation of Type VII Secretion Systems. Genome Biol Evol. 2017;9:398-413 pubmed publisher
    ..have a distinct secretion system, termed type VII (T7SS), which is encoded by paralogous chromosomal loci (ESX) and associated with pathogenesis, conjugation, and metal homeostasis...
  70. Furujo M, Kosuga M, Okuyama T. Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI: 10-Year follow up. Mol Genet Metab Rep. 2017;13:69-75 pubmed publisher
    Early initiation of enzyme replacement therapy (ERT) has demonstrated clinical benefit in patients with mucopolysaccharidosis type VI (MPS VI), a progressive, multisystem autosomal recessive lysosomal disorder caused by N-..
  71. Hendriksz C, Parini R, AlSayed M, Raiman J, Giugliani R, Mitchell J, et al. Impact of long-term elosulfase alfa on activities of daily living in patients with Morquio A syndrome in an open-label, multi-center, phase 3 extension study. Mol Genet Metab. 2018;123:127-134 pubmed publisher
    Long-term safety and efficacy of elosulfase alfa enzyme replacement therapy (ERT) were assessed in 173 patients with Morquio A syndrome (mucopolysaccharidosis IVA) in a 96-week, open-label, multi-center, phase 3 extension study (MOR-005) ..
  72. Rudders S, Gaspar J, Madore R, Voland C, Grall F, Patel A, et al. ESE-1 is a novel transcriptional mediator of inflammation that interacts with NF-kappa B to regulate the inducible nitric-oxide synthase gene. J Biol Chem. 2001;276:3302-9 pubmed
    ..Finally, in a mouse model of endotoxemia, associated with acute vascular inflammation, ESE-1 is strongly expressed in vascular endothelium and smooth muscle cells. In summary, ESE-1 represents a novel mediator of vascular inflammation. ..
  73. Kishnani P, Dickson P, Muldowney L, Lee J, Rosenberg A, Abichandani R, et al. Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction. Mol Genet Metab. 2016;117:66-83 pubmed publisher
    ..Complications due to immune responses to ERT are being recognized with increasing experience and lengths of exposure to ERTs to treat several LSDs...
  74. Pandey H, Tripathi S, Srivastava K, Tripathi D, Srivastava M, Kant S, et al. Characterization of culture filtrate proteins Rv1197 and Rv1198 of ESAT-6 family from Mycobacterium tuberculosis H37Rv. Biochim Biophys Acta Gen Subj. 2017;1861:396-408 pubmed publisher
    We have characterized two immunogenic proteins, Rv1197 and Rv1198, of the Esx-5 system of the ESAT-6 family of Mycobacterium tuberculosis H37Rv. The complex formation between Rv1197 and Rv1198 was characterized by biophysical techniques...
  75. Yu X, Wu Y, Liu X, Huang X, Hou X, Wang J, et al. Cell-Free RNA Content in Peripheral Blood as Potential Biomarkers for Detecting Circulating Tumor Cells in Non-Small Cell Lung Carcinoma. Int J Mol Sci. 2016;17: pubmed
    ..The mRNA levels of four candidate genes, cytokeratin 7 (CK7), E74-like factor 3 (ELF3), epidermal growth factor receptor (EGFR), and erythropoietin-producing hepatocellular carcinoma ..
  76. Barczak A, Avraham R, Singh S, Luo S, Zhang W, Bray M, et al. Systematic, multiparametric analysis of Mycobacterium tuberculosis intracellular infection offers insight into coordinated virulence. PLoS Pathog. 2017;13:e1006363 pubmed publisher
    ..Strikingly, mutants defective in two well-known virulence factors, the ESX-1 protein secretion system and the virulence lipid phthiocerol dimycocerosate (PDIM), clustered together...
  77. Stroobants S, Damme M, Van der Jeugd A, Vermaercke B, Andersson C, Fogh J, et al. Long-term enzyme replacement therapy improves neurocognitive functioning and hippocampal synaptic plasticity in immune-tolerant alpha-mannosidosis mice. Neurobiol Dis. 2017;106:255-268 pubmed publisher
    ..Immune-tolerant LAMAN knockout mice were developed to evaluate the effects of enzyme replacement therapy (ERT) by prolonged administration of recombinant human enzyme...
  78. Broomfield A, Fletcher J, Hensman P, Wright R, Prunty H, Pavaine J, et al. Rapidly Progressive White Matter Involvement in Early Childhood: The Expanding Phenotype of Infantile Onset Pompe?. JIMD Rep. 2018;39:55-62 pubmed publisher
    ..patient, immunomodulated with rituximab and methotrexate at birth, who despite an initial good clinical response to ERT, at the age of just under 4 years, presented with evolving spasticity in the lower limbs...
  79. Dallenga T, Repnik U, Corleis B, Eich J, Reimer R, Griffiths G, et al. M. tuberculosis-Induced Necrosis of Infected Neutrophils Promotes Bacterial Growth Following Phagocytosis by Macrophages. Cell Host Microbe. 2017;22:519-530.e3 pubmed publisher
    ..We found that Mtb induces necrosis of human neutrophils in an ESX-1-dependent manner, and neutrophil-produced reactive oxygen species (ROS) drive this necrosis...
  80. Kim H, Montejo L, Jia J, Hielscher A. Frequency-domain optical tomographic image reconstruction algorithm with the simplified spherical harmonics (SP3) light propagation model. Int J Therm Sci. 2017;116:265-277 pubmed publisher
    ..coefficients (FD-SPN) that approximates the frequency-domain equation of radiative transfer (FD-ERT)...
  81. Kim H, Kim H, Kim K, German M, Kim H. Ectopic serotonin production in β-cell specific transgenic mice. Biochem Biophys Res Commun. 2018;495:1986-1991 pubmed publisher
    ..we showed the ectopic serotonin (5-HT) production in β-cells of RIP-CreMgn, MIP-GFP, and MIP-Cre/ERT mice...
  82. Lee S, Bahn J, Choi C, Whitlock N, English A, Safe S, et al. ESE-1/EGR-1 pathway plays a role in tolfenamic acid-induced apoptosis in colorectal cancer cells. Mol Cancer Ther. 2008;7:3739-50 pubmed publisher
    ..These results show that activation of ESE-1 via enhanced nuclear translocation mediates tolfenamic acid-induced EGR-1 expression, which plays a critical role in the activation of apoptosis. ..
  83. Chen Z, Hu Y, Cumming B, Lu P, Feng L, Deng J, et al. Mycobacterial WhiB6 Differentially Regulates ESX-1 and the Dos Regulon to Modulate Granuloma Formation and Virulence in Zebrafish. Cell Rep. 2016;16:2512-24 pubmed publisher
    ..Here, we provide evidence that WhiB6 differentially regulates the ESX-1 and DosR regulons through its Fe-S cluster...
  84. Najib S, Fadili A, Mehdi K, Riss J, Makan A. Contribution of hydrochemical and geoelectrical approaches to investigate salinization process and seawater intrusion in the coastal aquifers of Chaouia, Morocco. J Contam Hydrol. 2017;198:24-36 pubmed publisher
    ..were analyzed for major chemical elements during January 2012 and, secondly, 10 electrical resistivity tomography (ERT) profiles were performed perpendicularly to the coastal fringe...
  85. Tsai A, Hung Y, Harding C, Koeller D, Wang J, Wong L. Next generation deep sequencing corrects diagnostic pitfalls of traditional molecular approach in a patient with prenatal onset of Pompe disease. Am J Med Genet A. 2017;173:2500-2504 pubmed publisher
    ..despite the absence of molecular confirmation by traditional Sanger sequencing), enzyme replacement therapy (ERT) for Pompe disease was initiated...
  86. Subramaniam M, Pitel K, Bruinsma E, Monroe D, Hawse J. TIEG and estrogen modulate SOST expression in the murine skeleton. J Cell Physiol. 2017;: pubmed publisher
    ..in the hormonal milieu affect SOST expression, we performed ovariectomy (OVX) and estrogen replacement therapy (ERT) studies in WT and TIEG KO mice followed by miRNA and mRNA sequencing of cortical and trabecular compartments of ..
  87. Kar A, Gutierrez Hartmann A. ESE-1/ELF3 mRNA expression associates with poor survival outcomes in HER2+ breast cancer patients and is critical for tumorigenesis in HER2+ breast cancer cells. Oncotarget. 2017;8:69622-69640 pubmed publisher
    ESE-1/Elf3 and HER2 appear to establish a positive feedback regulatory loop, but the precise role of ESE-1 in HER2+ breast tumorigenesis remains unknown...
  88. Rastall D, Amalfitano A. Current and Future Treatments for Lysosomal Storage Disorders. Curr Treat Options Neurol. 2017;19:45 pubmed publisher
    ..disorders that are a testing ground for the invention of novel therapeutics including enzyme replacement therapy (ERT), substrate reduction therapy (SRT), gene therapy, and hematopoietic stem cell transplant (HSCT)...
  89. Kanters T, Van der Ploeg A, Kruijshaar M, Rizopoulos D, Redekop W, Rutten van Mӧlken M, et al. Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease. Orphanet J Rare Dis. 2017;12:179 pubmed publisher
    ..Enzyme replacement therapy (ERT) with alglucosidase alfa is disease specific and the only medicinal product authorized for the treatment of Pompe ..
  90. Cabral A, Fischer D, Vermeij W, Backendorf C. Distinct functional interactions of human Skn-1 isoforms with Ese-1 during keratinocyte terminal differentiation. J Biol Chem. 2003;278:17792-9 pubmed
    ..Apparently, the human Skn-1 locus encodes multifunctional protein isotypes, subjected to biochemical cross-talk, which are likely to play a major role in the fine-tuning of keratinocyte terminal differentiation. ..
  91. Bock M, Hinley J, Schmitt C, Wahlicht T, Kramer S, Southgate J. Identification of ELF3 as an early transcriptional regulator of human urothelium. Dev Biol. 2014;386:321-30 pubmed publisher
    ..The analysis identified ELF3 as a candidate transcriptional regulator involved in human urothelial cytodifferentiation...